Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COR32
- Development stage
- Preclinical
- Lead developer
- Universitätsklinikum Köln
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
COR32 (also known as COR32_1_C2) is a human monoclonal antibody being developed by the University Hospital of Cologne for the prevention and treatment of BK polyomavirus (BKPyV) infection and associated complications, such as polyomavirus-associated nephropathy (PyVAN) in kidney transplant recipients. Isolated from memory B cells of kidney transplant recipients, COR32 targets the major capsid protein VP1 of BKPyV. It exhibits potent cross-neutralizing activity against all major BKPyV genotypes (I-IV), making it a promising therapeutic candidate to prevent premature graft function loss in transplant patients.
02
Targets
Norovirus VP1
Beyond the preview
Go deeper on COR32.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COR32.